Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory bowel disease
Biotech
Lilly inks $50M deal for biotech's FXR program
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat IBD, sending the biotech's stock up 244%.
Gabrielle Masson
Feb 26, 2025 5:35am
Sanofi shows how $500M IBD bet compares to Merck, Roche rivals
Feb 24, 2025 8:11am
GI-focused CRO boosts trial tech with adaptive software
Feb 3, 2025 11:40am
Sanofi, Teva tout midstage win for TL1A antibody in Crohn’s, UC
Dec 17, 2024 10:30am
AbbVie acquires oral peptide biotech Nimble for $200M
Dec 13, 2024 10:38am
Biotechs behind J&J-bought Yellow Jersey partner on IBD drug
Nov 15, 2024 8:30am
